<DOC>
	<DOCNO>NCT01371344</DOCNO>
	<brief_summary>The purpose study , follow study FG506-CL-0403 , see safe effective Modigraf® ( Part A ) see safe effective change child 's medication Modigraf® Prograf® ( Part B ) .</brief_summary>
	<brief_title>A Paediatric , Open , Follow Study With Modigraf Examining Safety Efficacy de Novo Allograft Recipients</brief_title>
	<detailed_description>To monitor safety efficacy Modigraf® ( tacrolimus granule ) stable paediatric allograft recipient ( Part A ) monitor dose change tacrolimus whole blood trough level conversion Modigraf base Immunosuppression regimen Prograf® base Immunosuppression regimen ( Part B ) .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>F506CL0404 Part A Subject ≤12 year age enrolment study F506CL0403 Subject receive least one dose Modigraf F506CL0403 study F506CL0404 Part B Subject receive least one dose Modigraf F506CL0403 study Subject participate F506CL0404 Part A Subject continuously dose Twice daily ( BID ) Modigraf since End Study Visit Part A ( ESVA ) F506CL0404 Part A Subject stable dose change precede 2 week F506CL0404 Part A As subject include study conform exclusion criterion study F506CL0403 , hence specific exclusion criterion relevant study F506CL0404 Part B There specific exclusion criterion study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Liver Transplantation</keyword>
	<keyword>Kidney Transplantation</keyword>
	<keyword>Heart Transplantation</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>